Cardiovascular

Pelacarsen (TQJ230)

Novartis / Ionis

Antisense oligonucleotide reducing Lp(a) by ~80%. Lp(a)HORIZON Phase 3 cardiovascular outcomes trial with 8,325 patients. Data expected H1 2026 — first outcomes trial to test the Lp(a) lowering hypothesis.

Elevated Lipoprotein(a)ASCVD

Linked Studies

NCT04023552PrimaryACTIVE_NOT_RECRUITINGPHASE3

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

Cardiovascular Disease and Lipoprotein(a)Updated May 2026

Loading comments…

Also Known As

Development codes

TQJ230

Other names

pelacarsen

Search all trials →Request coverage update